Equities Analysts Issue Forecasts for Masimo Co.’s FY2024 Earnings (NASDAQ:MASI)

Masimo Co. (NASDAQ:MASI) – Investment analysts at Zacks Research upped their FY2024 EPS estimates for Masimo in a research report issued on Tuesday, August 27th. Zacks Research analyst I. Bandyopadhyay now forecasts that the medical equipment provider will post earnings of $3.81 per share for the year, up from their prior estimate of $3.59. The consensus estimate for Masimo’s current full-year earnings is $3.63 per share. Zacks Research also issued estimates for Masimo’s Q4 2024 earnings at $1.35 EPS, Q1 2025 earnings at $0.82 EPS, Q2 2025 earnings at $0.95 EPS, Q3 2025 earnings at $1.13 EPS, Q4 2025 earnings at $1.18 EPS, FY2025 earnings at $4.08 EPS, Q1 2026 earnings at $1.18 EPS, Q2 2026 earnings at $1.17 EPS and FY2026 earnings at $4.42 EPS.

Masimo (NASDAQ:MASI) last released its quarterly earnings results on Tuesday, August 6th. The medical equipment provider reported $0.86 EPS for the quarter, topping the consensus estimate of $0.77 by $0.09. Masimo had a return on equity of 13.26% and a net margin of 4.01%. The business had revenue of $496.30 million during the quarter, compared to analysts’ expectations of $493.92 million. During the same quarter in the prior year, the business earned $0.62 earnings per share. The company’s quarterly revenue was up 9.0% compared to the same quarter last year.

Several other research firms also recently weighed in on MASI. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research note on Wednesday, August 7th. Piper Sandler increased their price objective on Masimo from $160.00 to $165.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $144.67.

Masimo Trading Down 1.7 %

Shares of MASI stock opened at $116.54 on Wednesday. The business’s fifty day moving average price is $117.10 and its 200 day moving average price is $127.08. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.31 and a quick ratio of 1.31. The firm has a market capitalization of $6.20 billion, a PE ratio of 79.28 and a beta of 0.97. Masimo has a 1-year low of $75.22 and a 1-year high of $153.93.

Institutional Trading of Masimo

Several hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of Masimo by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 4,781,343 shares of the medical equipment provider’s stock worth $560,421,000 after purchasing an additional 26,473 shares in the last quarter. Capital Research Global Investors increased its stake in shares of Masimo by 6.4% during the 4th quarter. Capital Research Global Investors now owns 2,269,189 shares of the medical equipment provider’s stock worth $265,972,000 after purchasing an additional 136,617 shares during the last quarter. Massachusetts Financial Services Co. MA increased its holdings in shares of Masimo by 6.2% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,607,310 shares of the medical equipment provider’s stock valued at $188,393,000 after acquiring an additional 93,861 shares during the last quarter. Farallon Capital Management LLC boosted its holdings in shares of Masimo by 13.6% during the 1st quarter. Farallon Capital Management LLC now owns 1,489,563 shares of the medical equipment provider’s stock worth $218,742,000 after buying an additional 177,914 shares during the period. Finally, Thrivent Financial for Lutherans boosted its stake in Masimo by 42.1% during the 2nd quarter. Thrivent Financial for Lutherans now owns 1,217,357 shares of the medical equipment provider’s stock valued at $153,314,000 after purchasing an additional 360,497 shares during the period. 85.96% of the stock is currently owned by hedge funds and other institutional investors.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.